Pfizer

News

Pfizer/BioNTech say COVID-19 jab on track for approval by ye...

Pfizer and BioNTech have said their COVID-19 vaccine could be ready for regulators to review by October and approved by the end of the year after releasing more favourable data from an earl

News

Will new data make Pfizer's Lorbrena a ‘no-brainer’ in early...

Pfizer has taken a big step towards positioning Lorbrena as a worthy heir to its big-selling Xalkori drug in lung cancer, after beating its parent in a phase 3 trial.

News

NICE backs kidney cancer combination from Merck KGaA and Pfi...

NICE has said a combination of Merck KGaA’s Bavencio and Pfizer’s Inlyta should be available as a first line option for kidney cancer patients for NHS patients in England.

News

Pfizer ups guidance as it prepares to sell off generics divi...

Pfizer has cautiously upped its guidance despite second quarter figures showing a slip in sales and profitability compared with the same period last year.

News

US places $1.95 billion order for Pfizer/BioNTech’s COVID-19...

The US government has agreed to pay Pfizer and BioNTech $1.95 billion to secure access to 100 million doses of their coronavirus vaccine on approval, just days after promising

News

Controversy as pharma execs predict profits from COVID-19 va...

Concerns have emerged about access to some potential COVID-19 vaccines after pharma executives from three companies said they expect to make profits from their products in evidence to a US

Pfizer/BioNTech say COVID-19 jab on track for approval by ye...

Will new data make Pfizer's Lorbrena a ‘no-brainer’ in early...

NICE backs kidney cancer combination from Merck KGaA and Pfi...

Pfizer ups guidance as it prepares to sell off generics divi...

US places $1.95 billion order for Pfizer/BioNTech’s COVID-19...

Controversy as pharma execs predict profits from COVID-19 va...

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Pfizer

Editor's Picks